Related references
Note: Only part of the references are listed.Organoids as an in vitro model of human development and disease
Aliya Fatehullah et al.
NATURE CELL BIOLOGY (2016)
Developing in vitro models of human ductal carcinoma in situ from primary tissue explants
Daniel D. Brown et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Multiple Molecular Subtypes of Triple-Negative Breast Cancer Critically Rely on Androgen Receptor and Respond to Enzalutamide In Vivo
Valerie N. Barton et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Targeting a cell state common to triple-negative breast cancers
Markus K. Muellner et al.
MOLECULAR SYSTEMS BIOLOGY (2015)
The Proteomic Landscape of Triple-Negative Breast Cancer
Robert T. Lawrence et al.
CELL REPORTS (2015)
Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model
Bhagwan Yadav et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2015)
Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
Matthew D. Burstein et al.
CLINICAL CANCER RESEARCH (2015)
Evaluation of Impermeant, DNA-Binding Dye Fluorescence as a Real-Time Readout of Eukaryotic Cell Toxicity in a High Throughput Screening Format
Lucius Chiaraviglio et al.
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES (2014)
The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma
Andrew Spencer et al.
BLOOD (2014)
Quantitative Optical Imaging of Primary Tumor Organoid Metabolism Predicts Drug Response in Breast Cancer
Alex J. Walsh et al.
CANCER RESEARCH (2014)
New Strategies for Triple-Negative Breast Cancer-Deciphering the Heterogeneity
Ingrid A. Mayer et al.
CLINICAL CANCER RESEARCH (2014)
Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes
Brian D. Lehmann et al.
JOURNAL OF PATHOLOGY (2014)
Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis
Alberto Ocana et al.
PLOS ONE (2014)
Patient-derived models of acquired resistance can identify effective drug combinations for cancer
Adam S. Crystal et al.
SCIENCE (2014)
Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility
Min Yu et al.
SCIENCE (2014)
Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies
Bhagwan Yadav et al.
SCIENTIFIC REPORTS (2014)
A New Bliss Independence Model to Analyze Drug Combination Data
Wei Zhao et al.
JOURNAL OF BIOMOLECULAR SCREENING (2014)
Biological subtypes of triple-negative breast cancer are associated with distinct morphological changes and clinical behaviour
Zeinab Elsawaf et al.
BREAST (2013)
Inconsistency in large pharmacogenomic studies
Benjamin Haibe-Kains et al.
NATURE (2013)
Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia
Tea Pemovska et al.
CANCER DISCOVERY (2013)
Modeling precision treatment of breast cancer
Anneleen Daemen et al.
GENOME BIOLOGY (2013)
Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
James S. Duncan et al.
CELL (2012)
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett et al.
NATURE (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Subtype and pathway specific responses to anticancer compounds in breast cancer
Laura M. Heiser et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Triple negative breast cancer: unmet medical needs
Sumanta Kumar Pal et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
A Multifunctional 3D Co-Culture System for Studies of Mammary Tissue Morphogenesis and Stem Cell Biology
Jonathan J. Campbell et al.
PLOS ONE (2011)
The Association of CCND1 Overexpression and Cisplatin Resistance in Testicular Germ Cell Tumors and Other Cancers
Elodie E. Noel et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Human keratinocytes are efficiently immortalized by a Rho kinase inhibitor
Sandra Chapman et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Protein kinase C isoforms: Multi-functional regulators of cell life and death
Mary E. Reyland
FRONTIERS IN BIOSCIENCE-LANDMARK (2009)
NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cells
Noritaka Yamaguchi et al.
CANCER RESEARCH (2008)
Molecular dependence of estrogen receptor-negative breast cancer on a Notch-survivin signaling axis
Connie W. Lee et al.
CANCER RESEARCH (2008)
Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors
L. S. Steelman et al.
ONCOGENE (2008)
Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer
J. Bostner et al.
ONCOGENE (2007)
Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance
George W. Small et al.
CANCER RESEARCH (2007)
Descriptive analysis of estrogen receptor (ER)negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype - A population-based study from the California Cancer Registry
Katrina R. Bauer et al.
CANCER (2007)
The STAT3 oncogene as a predictive marker of drug resistance
Benjamin Barre et al.
TRENDS IN MOLECULAR MEDICINE (2007)
Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas
Bas Kreike et al.
BREAST CANCER RESEARCH (2007)
Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer
Yue Y. Shi et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Prediction of anticancer drug potency from expression of genes involved in growth factor signaling
ZY Dai et al.
PHARMACEUTICAL RESEARCH (2006)
The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers
KW Cheng et al.
NATURE MEDICINE (2004)
Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44/42-MAPK
GW Small et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells
PJ Real et al.
ONCOGENE (2002)
Share Paper
